Edwards Lifesciences (NYSE:EW) SVP Sells 544 Shares of Stock

Key Points

• Insider sale: Senior Vice President Andrew Dahl sold 544 Edwards Lifesciences shares for approximately $49,537, reducing his ownership by 3.53% to 14,868 shares.
• Financial performance: Edwards reported quarterly EPS of $0.78, beating estimates by $0.04, while revenue rose 13.6% year over year to $1.74 billion.
• Market outlook: Shares rose 0.7% to $90.86, and analysts maintain a “Moderate Buy” consensus with an average price target of $100.27; institutional investors own 79.46% of the stock.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) SVP Andrew Dahl sold 544 shares of the stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company's stock, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Edwards Lifesciences Stock Up 0.7%

Shares of NYSE EW traded up $0.65 during mid-day trading on Monday, reaching $90.86. 4,047,490 shares of the company's stock were exchanged, compared to its average volume of 4,695,761. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $52.32 billion, a price-to-earnings ratio of 52.22, a PEG ratio of 2.37 and a beta of 0.85. The business has a fifty day simple moving average of $89.54 and a 200 day simple moving average of $85.08.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences's quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Institutional Trading of Edwards Lifesciences

A number of institutional investors have recently made changes to their positions in EW. California State Teachers Retirement System lifted its position in Edwards Lifesciences by 9,187.8% during the 2nd quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company's stock worth $7,323,828,000 after buying an additional 80,090,362 shares in the last quarter. BlackRock Inc. bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $5,318,092,000. Bank of New York Mellon Corp bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $1,274,082,000. Norges Bank acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $803,686,000. Finally, Bank of America Corp DE acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at about $605,397,000. Institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on EW shares. Citigroup boosted their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. UBS Group began coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a "buy" rating and a $110.00 price target on the stock. Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Finally, Leerink Partners raised Edwards Lifesciences from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source